

Curriculum Vitae

PERSONALITY

Name: Bhumsuk Keam

Address: Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongnogu, Seoul, 110-744, Korea

EDUCATION

Mar. 1996- Feb. 1998 Premedical School, Seoul National University, Seoul, Korea

Mar. 1998- Feb. 2002 Seoul National University College of Medicine, Seoul, Korea
With Honor

Sep. 2004- Feb.2007 Course of Degree of Master in Medicine (Internal Medicine),
Seoul National University College of Medicine, Seoul, Korea

Mar.2007- Aug.2014 Course of Ph.D. in Medicine (Internal Medicine),
Seoul National University College of Medicine, Seoul, Korea

TRAINING AND POSITION

Mar. 2002- Feb. 2003 Internship, Seoul National University Hospital, Seoul, Korea

Mar. 2003- Feb. 2007 Residency Course at Department of Internal Medicine,
Seoul National University Hospital, Seoul, Korea

Apr. 2007- Apr. 2010 Public Health Doctor, Department of Internal Medicine,
National Sorokdo Hospital, Chonnam, Korea

May 2008- Apr.2010 Public Health Doctor, Korean National Institutes of Health,
Seoul, Korea

May 2010-Feb. 2011 Clinical Fellow, Division of Hematology and Medical Oncology,
Department of Internal Medicine, Seoul National University
Hospital, Seoul, Korea

Mar. 2011- Feb. 2015 Clinical Assistant Professor,
Division of Hematology and Medical Oncology,
Department of Internal Medicine, Seoul National University
Hospital, Seoul, Korea

Mar. 2015- Present Clinical Associate Professor,
Division of Hematology and Medical Oncology,
Department of Internal Medicine, Seoul National University
Hospital, Seoul, Korea

PUBLICATION (selected)

- 1) Ock CY, **Keam B**, Kim S, Lee JS, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS. Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T cell infiltration. Clin Cancer Res. 2016 Jan 27. [Epub ahead of print]
- 2) Ock CY, Kim S, **Keam B**, Kim M, Kim TM, Kim JH, Jeon YK, Lee JS, Kwon SK, Hah JH, Kwon TK, Kim DW, Wu HG, Sung MW, Heo DS. PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Oncotarget. 2016 Feb 17 [Epub ahead of print]
- 3) Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, **Keam B**, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ; METEOR Investigators. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 5;373(19):1814-23.
- 4) Song A, Kim TM, Kim DW, Kim S, **Keam B**, Lee SH, Heo DS. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer. Clin Cancer Res 2015 May 15;21(10):2379-87
- 5) Won JK, **Keam B**, Koh J, Cho HJ, Jeon YK, Kim TM, Lee SH, Lee DS, Kim DW, Chung DH. Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor. Ann Oncol. 2015 Feb;26(2):348-54
- 6) Lee JK, Hahn S, Kim DW, Suh KJ, **Keam B**, Kim TM, Lee SH, Heo DS. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. JAMA. 2014 Apr 9;311(14):1430-7.